European Heart Journal Advance Access published online on November 25, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi673
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Members of the Board of the European Society of Cardiology
* To whom correspondence should be addressed. Summary Reperfusion therapy in ST-segment elevation myocardial infarction (STEMI) is the most important component of treatment, as it strongly influences short- and long-term patient outcome. The main objective of healthcare providers should be to achieve at least 75% of reperfusion therapy applied to patients suffering from STEMI in a timely manner, and preferably within the first 3 h after onset of symptoms. Establishing networks of reperfusion at regional and national level, implying close collaboration between all the actors involved in reperfusion therapy, namely hospitals, departments of cardiology, PCI centres, emergency medical systems (EMS), (para)medically staffed ambulances, private cardiologists, primary care physicians, etc., is a key issue. All forms of reperfusion, depending on local facilities, need to be available to patients. Protocols must be written and agreed for the strategy of reperfusion to be applied within a network. Early diagnosis of STEMI is essential and is best achieved by rapid ECG recording and interpretation at first medical contact, wherever this contact takes place (hospital or ambulance). Tele-transmission of ECG for immediate interpretation by experienced cardiologists is an alternative. Primary PCI is the preferred reperfusion option if it can be performed by experienced staff within 90 min after first medical contact. Thrombolytic treatment, administered if possible in the pre-hospital setting, is a valid option if PCI cannot be performed in a timely manner, particularly within the first 3 h following onset of symptoms. Thrombolysis is not the end of the reperfusion therapy. Rescue PCI must be performed in the case of thrombolysis failure. Next-day PCI after successful thrombolysis has been proven efficacious. Quality control is important for monitoring the efficacy of networks of reperfusion. All elements that influence time to reperfusion must be taken into account, particularly transfer delays, in-hospital delays, and door-to-balloon or door-to-needle times. The rate of reperfusion achieved must also be taken into consideration. Professional organizations such as the European Society of Cardiology (ESC) have the responsibility to impart this message to the cardiology community, and inform politicians and health authorities about the best possible strategy to achieve reperfusion therapy.
Received November 2, 2005
Accepted November 10, 2005
ESC Report
Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology
Jean-Pierre Bassand 1 *,
Nicolas Danchin 2,
Gerasimos Filippatos 2,
Anselm Gitt 1,
Christian Hamm 1,
Sigmund Silber 3,
Marco Tubaro 2,
and
Franz Weidinger 3
2 Representatives of ESC Working Group 27 Acute Cardiac Care
3 Representatives of ESC Working Group 10 Interventional Cardiology
Jean-Pierre Bassand, E-mail: jean-pierre.bassand{at}ufc-chu.univ-fcomte.fr
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S N Khan, P Murray, L McCormick, L S Sharples, P Salahshouri, J Scott, and P M Schofield Paramedic-led prehospital thrombolysis is safe and effective: the East Anglian experience Emerg. Med. J., June 1, 2009; 26(6): 452 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schmitt, G. Duray, B. J. Gersh, and S. H. Hohnloser Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications Eur. Heart J., May 1, 2009; 30(9): 1038 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Terkelsen, E H Christiansen, J T Sorensen, S D Kristensen, J F Lassen, L Thuesen, H R Andersen, W Vach, and T T Nielsen Primary PCI as the preferred reperfusion therapy in STEMI: it is a matter of time Heart, March 1, 2009; 95(5): 362 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Saia, C Marrozzini, P Ortolani, T Palmerini, P Guastaroba, P Cortesi, P C Pavesi, G Gordini, L G Pancaldi, N Taglieri, et al. Optimisation of therapeutic strategies for ST-segment elevation acute myocardial infarction: the impact of a territorial network on reperfusion therapy and mortality Heart, March 1, 2009; 95(5): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Danchin, E. Durand, and D. Blanchard Pre-hospital thrombolysis in perspective Eur. Heart J., December 1, 2008; 29(23): 2835 - 2842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: Eur. Heart J., December 1, 2008; 29(23): 2909 - 2945. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wienbergen, J. Senges, and A. K. Gitt Should We Prescribe Statin and Aspirin for Every Diabetic Patient?: Is it time for a polypill? Diabetes Care, February 1, 2008; 31(Supplement_2): S222 - S225. [Full Text] [PDF]
|
|
|
|
|
|
Y. Bravo Vergel, S. Palmer, C. Asseburg, E. Fenwick, M. de Belder, K. Abrams, and M. Sculpher Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis Heart, October 1, 2007; 93(10): 1238 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Faxon Development of Systems of Care for ST-Elevation Myocardial Infarction Patients: Current State of ST-Elevation Myocardial Infarction Care Circulation, July 10, 2007; 116(2): e29 - e32. [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Dirksen, G. J. Laarman, M. L. Simoons, and D. J.G.M. Duncker Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies Cardiovasc Res, June 1, 2007; 74(3): 343 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Widimsky, D. Bilkova, M. Penicka, M. Novak, M. Lanikova, V. Porizka, L. Groch, M. Zelizko, T. Budesinsky, M. Aschermann, et al. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 trial Eur. Heart J., March 2, 2007; 28(6): 679 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Huynh, J. O'Loughlin, L. Joseph, E. Schampaert, S. Rinfret, M. Afilalo, S. Kouz, B. Cantin, M. Nguyen, M. J. Eisenberg, et al. Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: results from the AMI-QUEBEC Study Can. Med. Assoc. J., December 5, 2006; 175(12): 1527 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mandelzweig, A. Battler, V. Boyko, H. Bueno, N. Danchin, G. Filippatos, A. Gitt, D. Hasdai, Y. Hasin, J. Marrugat, et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004 Eur. Heart J., October 1, 2006; 27(19): 2285 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Danchin Should intravenous thrombolysis keep a place in the treatment of acute ST-elevation myocardial infarction? Eur. Heart J., May 2, 2006; 27(10): 1131 - 1133. [Full Text] [PDF]
|
|